• +1(847) 967-6000
  • Resources
  • Blog
  • News
  • Events
  • Careers
Tadgh Prendeville to Assume the Role of President and CEO at Regis Technologies, Inc.Tadgh Prendeville to Assume the Role of President and CEO at Regis Technologies, Inc.Tadgh Prendeville to Assume the Role of President and CEO at Regis Technologies, Inc.Tadgh Prendeville to Assume the Role of President and CEO at Regis Technologies, Inc.
  • Home
  • About Us
    • About Regis
    • Our Team
    • Facility Tour
    • Manufacturing Facility Details
    • Our Distributors
  • Custom Pharma
    • API SOLUTIONS
      • IND Enabling Supply
      • Clinical Trial Material
      • Commercial API
      • Orphan & Fast Track
    • CONTRACT DEVELOPMENT & CGMP MANUFACTURING
      • Process Chemistry
      • Analytical Development
      • Project Management
      • Quality Assurance
      • CGMP Scale Up
      • Custom Manufacturing
      • HPAPI Manufacturing
      • Micronization
      • Quality Control
    • PHARMA SERVICES
      • Solid State Chemistry
      • Stability Services
      • Impurity Services
      • Fate and Purge
      • Free Chiral Screening
  • Chromatography Products
    • CHROMATOGRAPHY COLUMNS
      • Chiral HPLC & SFC Columns
      • Achiral SFC Columns
      • Reversed-Phase HPLC Columns
      • Immobilized Artificial
        Membrane (IAM) Chromatography
      • Free Chiral Screening
    • SPECIALTY REAGENTS
      • Ion Pairing Reagents
      • Derivatizing Reagents
  • IMAGING REAGENTS
    • Coelenterazine
    • Luciferin
    • 4-Chloro-1-Naphthol
  • Contact Us
  • HOME
  • ABOUT US
    • About Regis
    • Our Team
    • Facility Tour
    • Manufacturing Facility Details
    • Our Distributors
  • CHROMATOGRAPHY PRODUCTS
    • Chromatography Columns
      • Chiral HPLC & SFC Columns
      • Achiral SFC Columns
      • Reversed-Phase HPLC Columns
      • Immobilized Artificial Membrane (IAM) Chromatography
    • Specialty Reagents
      • Ion Pairing Reagents
      • Derivatizing Reagents
  • IMAGING REAGENTS
    • Coelenterazine
    • Luciferin
    • 4-Chloro-1-Naphthol
  • CUSTOM PHARMA
    • API Solutions
      • IND Enabling Supply
      • Clinical Trial Material
      • Commercial API
      • Orphan & Fast Track
    • Contract Development & CGMP Manufacturing
      • Process Chemistry
      • CGMP Scale Up
      • Analytical Development
      • Custom CGMP API Manufacturing
      • Project Management
      • HPAPI Manufacturing
      • Micronization
      • Quality Assurance
      • Quality Control
    • Pharma Services
      • Solid State Chemistry
      • Stability Services
      • Impurity Services
      • Fate and Purge
      • Free Chiral Screening
  • CONTACT US
  • News
  • Blog
  • Resources
  • Events
  • Careers
0

Tadgh Prendeville to Assume the Role of President and CEO at Regis Technologies, Inc.

March 21, 2022
Tadgh Prendeville President and CEO Regis Technologies

Regis Technologies, Inc. today announced that Tadgh Prendeville has been appointed the new President and CEO of the company. Tadgh will succeed Louis Glunz IV and assume responsibilities on March 21, 2022.

 

Prendeville comes to Regis from ARx LLC, a family-owned CMDO company where he held the position of President. He is an experienced leader having helped deliver five FDA approvals through innovative pharmaceutical development at ARx LLC. “We are delighted to welcome Tadgh to Regis. His broad experience, proven history of delivering solutions to customers and excellent leadership skills make him an ideal person to lead Regis into the future,” said Jim Sullivan, Chairman of the Board of Directors for Regis Technologies.

Prendeville received his Master of Engineering Science from the University College of Dublin and earned an MBA from the University of Baltimore.

 

“I am excited to work with the Regis team of expert scientists and accomplished pharmaceutical professionals to continue delivering quality products and expedited pharmaceutical services to our customers. I want to congratulate Louis on a tremendous career at Regis.  His commitment to creating a GMP facility and investing in a number of capabilities including Analytical Development, Solid State Chemistry, Potent Compound Synthesis and Chiral Chromatography will leave an enduring legacy,” says Tadgh Prendeville, President and CEO of Regis Technologies.

 

Glunz will assume the role of Vice-Chairman of the Board of Directors for Regis Technologies and serve as a Strategic Advisor to Prendeville. He said ”The Glunz family remains committed to the Regis mission of expediting drugs to market. Tadgh will continue our values of a family-owned business and I look forward to working closely with him throughout this transition.”

 

Share

Information

  • Terms & Conditions
  • Site Map
  • Return Policy
  • Privacy Policy

About Us

  • About Regis
  • Services
  • Products
  • Upcoming Events

Contact Us

8210 Austin Ave
Morton Grove, IL 60053

+1(847) 967-6000
sales@registech.com

Find a Distributor

E-Mail Sign Up









    Website Created by Advanta Advertising, LLC.
    © 2023 Regis Technologies Inc. All Rights Reserved
    Contact Us
      0
      • Resources
      • Blog
      • News
      • Events
      • Careers

      [ Placeholder content for popup link ] WordPress Download Manager - Best Download Management Plugin